Eribulin rapidly reduces the aggressiveness of second primary breast cancer: a case report

The cytotoxic agent, eribulin represents a new standard of care in the treatment of heavily pretreated metastatic breast cancer patients. Here, we describe our experience with eribulin in a patient with a controlled primary breast cancer, who showed an aggressive recurrence of the primary tumor, including metastatic disease. Treatment management of the second primary tumor included six lines of chemotherapy and three lines of hormonal therapy, including eribulin as sixth line among all chemotherapies received. Eribulin treatment achieved a fast response to all metastatic sites and decelerated the aggressive evolution of the second disease.